STOCKS TELEGRAPH

Tag: TCON stock

  • After-Hours Brilliance: Unveiling TRACON Pharmaceuticals’ Financial Triumphs and Market Mastery

    After-Hours Brilliance: Unveiling TRACON Pharmaceuticals’ Financial Triumphs and Market Mastery

    TRACON Pharmaceuticals Inc., a well-known player in the biopharmaceutical sector, has recently garnered attention for its exceptional after-hours showing in the US stock market.

    This piece provides a comprehensive examination of the occurrence and the ensuing financial ramifications for the company and its stakeholders.

    Overview of Company

    TRACON Pharmaceuticals (TCON) is a clinical-stage biopharmaceutical company primarily focusing on the development and commercialization of novel targeted cancer therapeutics.

    The company’s unique cost-efficient, CRO-independent product development platform has made it a preferred partner for other life science companies.

    TRACON’s After-Hours Performance

    TRACON (TCON) demonstrated an impressive after-hours performance recently. The company’s stock saw a staggering post-market change of +131.25%, closing at 0.3700 USD. This substantial increase amounted to a post-market change of 0.2100 USD.

    Volume of Shares Traded

    The company’s after-hours trading session observed a high post-market volume of 15.736 million shares, indicating a strong interest from investors.

    This volume was slightly lower than the regular trading session, which saw a volume of 16.15 million shares, suggesting a consistent interest throughout the day.

    Regular Trading Session Performance

    Before the after-hours trading session, the regular trading session saw the company’s stock at 0.1600 USD. This price reflected a modest change of 0.95%, suggesting a stable market performance during regular trading hours.

    Yearly Performance

    When considering the stock’s recent activity, it is important to note its performance over the past year.

    TCON has faced challenges, with its performance marked by an -85.86% decline. This decline indicates that despite the recent after-hours surge, the company has had a tough year in the market.

    Product Development Platform

    One of TRACON’s key strengths lies in its product development platform. This platform is designed to generate non-dilutive capital, which essentially means financing that does not require the sale of the company’s shares.

    The company wants to license this platform to other companies, allowing them to transform their clinical operations.

    Anticipated Milestones

    TRACON has several key milestones to look forward to. These include the completion of the ENVASARC pivotal trial in the fourth quarter of 2023 and the release of updated response rate data before the end of the year. The final data from this trial is expected in mid-2024.

    Financial Results

    TRACON recently disclosed its financial outcomes for the third quarter concluding on September 30, 2023. The company declared a net income of $10.8 million during Q3 2023, contrasting with a net loss of $6.4 million recorded in the corresponding period of 2022.

    Conclusion

    The after-hours performance of TRACON Pharmaceuticals Inc. underlines the potential rewards and risks of after-hours trading.

    While the company’s stock demonstrated a noteworthy surge, it is essential to consider the broader context, including the company’s annual performance and the current market conditions.

    As always, prudent research and market analysis remain crucial for successful trading and investment decisions.

  • TRACON Pharmaceuticals, Inc. (TCON) Stock Nose-dived After Hours Following Financials Release.

    TRACON Pharmaceuticals, Inc. (TCON) Stock Nose-dived After Hours Following Financials Release.

    TRACON Pharmaceuticals, Inc. (TCON) is a leading late-clinical company focused on the development and marketing of cancer therapeutics along with treatment for macular degeneration and fibrotic diseases. Its pipeline candidate is Envafolimab used in treating sarcomas. TRC102 is in Phase 2 trials for lung cancer treatment and TJ004309 in Phase 1 trials for progressive solid tumors treatment.

    TCON stock price during the regular trading of March 15, 2022, is slightly up by 1.50% to be $2.7. Its price plummeted at the time of writing in the aftermarket session by 22.2%.

    TCON: Key Financials

    On March 15, 2022, TCON announced its fourth-quarter 2021 financial statement for the three months ended December 31, 2021. Some key highlights are as follows.

    Revenue

    No revenue was recorded by the company in the fourth fiscal quarter of 2021 and 2020. The analyst’s estimations for the revenue were $66.6 thousand and the company missed it.

    EPS

    Net loss (basic and diluted) for the fourth quarter of fiscal 2021 was $7.7 million or $0.40 per share compared to $4.3 million or $0.31 per share in the corresponding quarter of 2020. The company recorded a decline in its earnings over the year. It missed the target EPS by -%0.04

    TCON: Events and Happenings

    On March 11, 2022, TCON reported the participation of its CEO Charles Theuer at the Oppenheimer 32nd Annual Healthcare Conference being held on March 16, 2022. On March 10, 2022, TCON updated on preliminary patient dosage following the FDA’s endorsement regarding the modified ENVASARC protocol.

    On February 02, 2022, TCON issued a statement regarding the initiation of Phase 2 TRC102 along with chemoradiation in patients with NSCLC by the National Cancer Institute. On January 05, 2022, TCON informed about the presentation of its CEO at the Virtual H.C. Wainwright BIOCONNECT Conference held on January 10-13, 2022.

    Conclusion

    TCON stock showed a bearish trend during the past year as its stock down-performed by 70%. The company’s stock is declining in the aftermarket as it provided updates on its earnings and missed both revenue and EPS targets.

  • Tracon Pharmaceuticals, Inc. (TCON) Stock Dipped in Regular Trading, Here’s What you Should Know

    Tracon Pharmaceuticals, Inc. (TCON) is a leading clinical stage company engaged in the development and commercialization of oncology related therapies. The company also develops treatment for macular degeneration and fibrotic diseases. The lead product candidates is Envafolimab, an antibody injected subcutaneously for treatment of ENVASARC trial for sarcoma. TRC102 is another product in Phase 2 trial for the treatment of lung cancer. TJ004309 is in Phase 1 clinical trials for the treatment of progressive solid tumors.

    The price of TCON stock, at last check during the regular trading on December 27, 2021, was $3.00. the showed a notable decline of 13.86%.

    TCON: Events and Happenings

    On December 27, 2021, TCON reported that the Independent Data Monitoring Committee recommended continued accretion in both the units of envafolimab. Toleration level of Envafolimab was good, with only a minor adversity reported in some patients. On November 29, 2021, TCON announced that its collaborators Alphamab Oncology and 3D Medicines reported that envafolimab received marketing certification from the Chinese Administration.

    On November 11, 2021, TCON reported that the top management of the company presented at the Virtual Jefferies London Healthcare Conference. The conference held on November 18-19, 2021.

    TCON: Key Financials

    On November 03, 2021, TCON reported financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows

    Net loss per Share

    Basic and diluted net loss for the third quarter of 2021 was $7.0 million or $0.38 per share, as compared to $4.0 million or $0.38 for the same quarter of 2020.

    Total Current Assets

    Total current assets reported by the company for Q3 2021 were $31.1 million as compared to the same period prior year when they were $27.4 million.

    On October 11, 2021, TCON and Eucure Biopharma entered into a partnership for the research and development of YH001. It is used in treatment of soft tissue sarcoma. On September 13, 2021, TCON reported that the top management of the company presented at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit. The summit held on September 20, 2021.

    On September 07, 2021, reported that the top management of the company presented at the H.C. Wainwright 23rd Annual Global Investment Conference. It held on September 13-15, 2021. On September 02, 2021, TCON reported that the top management of the company presented at the Wells Fargo Healthcare Conference. The conference virtually held on September 9, 2021.

    Conclusion

    The price of TCON stock s 15% up in comparison to the past month but it remarkably declined in the regular trading. The decline is the result of uncertain market environment. Earlier the company reported positive outcomes from IDMC for Envasarc trials. The analysts believe the company’s strategies are strong to attract potential investment in the future.

  • TRACON Pharmaceuticals, Inc. (TCON) Stock Plummets Following Upsizing of Underwritten Public Offering

    TRACON Pharmaceuticals, Inc. (TCON) stock prices were down 4.27% as of the market closing on July 21st, 2021, bringing the price per share down to USD$4.93 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 23.33%, bringing it down to USD$3.78.

    Upsizing of Public Offering

    July 21st, 2021 saw the company announce the upsizing of its previously announced public offering as a result of the level of demand. The upsizing will consist of a firm commitment to purchase 3,926,702 shares of common stock, with each share being priced at USD$3.82. Furthermore, the agreement comes equipped with a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price. The closing of the public offering is expected to close on July 26th, 2021.

    Details of the Offering

    The public offering is expected to generate gross proceeds in the amount of roughly USD$15 million, before the deduction of expenses related to the offering and excluding the exercising of the over-allotment option. The capital raised is forecasted to be allocated towards the supporting of the continued clinical development of envafolimab, as well as for working capital and general corporate purposes.

    Orphan Drug Designation

    June 29th, 2021 saw the company announce the granting of Orphan Drug Designation to envafolimab by the U.S Food and Drug Administration. The innovative, single-domain antibody against PD-L1 is being developed for the treatment of patients with soft tissue sarcoma. This development followed the submissions of a revised application that consisted of data from the Phase 1 clinical trial from sarcoma patients treated with single-agent envafolimab.

    Basis of Envafolimab ODD

    The Orphan Drug Designation submission for the use of envafolimab in sarcoma included clinical data that signaled confirmed objective partial responses by RECIST with response durations exceeding six months. This promising development was observed in two out of five patients with refractory metastatic alveolar soft part sarcoma (ASPS), with the patients having been administered single-agent envafolimab in Phase 1 clinical trials. The trials were conducted by the company’s partner, 3D Medicines and Alphamab Oncology. The Phase 1 trials did not include patients with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) were not treated as part of Phase 1 trials.

    Future Outlook for TCON

    Armed with the added influx of capital generated from the company’s public offering, TCON is poised to capitalize on the opportunities afforded to it as a result of the granting of Orphan Drug Designation for its flagship treatment. Investors are hopeful that management will be able to facilitate the hasty commercialization and effective proliferation of the treatment as it continues to work closely with the FDA.

  • TRACON Pharmaceuticals (NASDAQ: TCON) Receives FDA TRC102 Orphan Drug Designation

    TRACON Pharmaceuticals (NASDAQ: TCON) Receives FDA TRC102 Orphan Drug Designation

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced today that it has received Orphan Drug Designation for TRC102 for the treatment of patients suffering from malignant Glioma and glioblastoma (GBM) from the US Food and Drug Administration (FDA). In the Orphan Drug Designation, the drug has been given the Orphan status. This status is given to the companies to provide them with financial benefits for the development of new drugs for the treatment of rare diseases.

    TRC102 is being examined in Phase 1 and Phase 2 clinical trials which were sponsored by the National Cancer Institute through a Cooperative Research and Development Agreement (CRADA). In Phase II, TRC102 was analyzed with Temodar chemotherapy. This study has been done on 19 patients who were suffering from progressive or recurrent GBM.

    Thes study has shown promising results and increase the time of survival in two patients for more than two years. Both patients have shown the activation of the DNA base excision repair pathway and shown hyperactivation of DNA damage response genes.

    Furthermore, TRC102 has also been analyzed in combination with chemotherapy and external beam radiotherapy in a Phase 1 study. 15 patients have participated in this study who have newly diagnosed non-squamous cell non-small cell lung cancer.

    TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) shares were trading up 9.29% at $4.94 during the trading session of Friday. TRACON Pharmaceuticals, Inc. (TCON) share price went from a low point around $0.95 to briefly over $6.37 in the past 52 weeks. It has traded up 420.00% from its 52-weeks low and moved down -22.45% from its 52-weeks high. TCON market cap has remained high, hitting $59.58 million at the time of writing.

    Orphan Drug Designation status for TRC102 will be helpful in providing the treatment for unmet medical needs of patients who are suffering from malignant glioma. TRACON Pharmaceuticals has committed to developing TRC102 with the help of the National Cancer Institute.